Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Capital Raise

Arcturus Therapeutics Shares Rise 9% After $50 Million Investment from Meiji Seika Pharma

Arcturus Therapeutics Secures $50 Million Investment from Meiji Seika Pharma at 80% Premium

+9.45% $8.36 when we broke this story → $9.15 at 9:33 AM ET, 16 Nov 2026

Arcturus Therapeutics has entered a $50 million securities purchase agreement with Meiji Seika Pharma, issuing over 2.4 million shares at a significant premium. This strategic investment coincides with an expanded collaboration focusing on pandemic preparedness in Japan and the licensing of self-amplifying mRNA technology.

Modern technologies, marketing, business analyst, manager's desk. Stock photo illustrating Arcturus Therapeutics' capital raise story.
Arcturus Therapeutics Holdings Inc. · Healthcare · Photo: AS_Photography / Pixabay
Key numbers
Deal value$50M
Share of market cap20.8%

Key highlights

  • $50.0 million gross proceeds through the sale of 2,466,395 common shares
  • Offer price of $20.27 per share represents an 80% premium to the 30-day average
  • Agreement includes a 365-day lock-up period and a 24-month standstill provision
  • Potential $11.1 million refund required if a definitive license is not signed by May 2027
  • Strategic alignment includes an MOU for Japanese pandemic preparedness and response

What Is the Capital Raise?

Arcturus Therapeutics (NASDAQ: ARCT) has finalized a $50.0 million equity financing through a private placement with Meiji Seika Pharma. The transaction involved the sale of 2,466,395 shares of common stock at a purchase price of $20.27 per share. This pricing reflects a substantial 80% premium over the 30-day average closing price through November 11, 2026. The agreement contains a unique clawback provision: if the companies do not execute a definitive license agreement by May 31, 2027, Arcturus must refund approximately $11.1 million of the premium to Meiji in either cash or common stock. Meiji is now subject to a one-year lock-up and a 9.9% ownership cap.

Use of Proceeds

  • Accelerate clinical development of ARCT-2601 for the treatment of OTC deficiency
  • Validate the next-generation LUNAR 2.0 messenger RNA delivery platform
  • Advance the company's existing cystic fibrosis respiratory program
  • Support manufacturing expertise and drug substance development for the mRNA pipeline
  • Provide working capital for the expanded Japanese collaboration and pandemic preparedness

Strategic Rationale

The investment cements a deepening partnership between Arcturus and Meiji, moving beyond their existing vaccine commercialization work. By securing capital at a significant premium to its current market valuation, Arcturus strengthens its balance sheet while minimizing shareholder dilution. The deal is part of a broader strategic framework that includes a license for self-amplifying mRNA technology and a Memorandum of Understanding for pandemic response in Japan. This collaboration leverages Arcturus' STARR technology to address undisclosed therapeutic areas, positioning the company as a key infrastructure partner for Japan's domestic healthcare security.

Business Overview

Based in San Diego, Arcturus Therapeutics is a clinical-stage biotechnology firm specializing in messenger RNA medicines for rare liver diseases and respiratory conditions. The company's platform is built on three pillars: LUNAR lipid-mediated delivery, STARR self-amplifying mRNA technology, and specialized manufacturing capabilities. Arcturus developed KOSTAIVE, the first self-amplifying mRNA COVID-19 vaccine to receive global approval. Its current pipeline includes high-priority programs for cystic fibrosis, ornithine transcarbamylase deficiency, and phenylketonuria, supported by a portfolio of over 500 patents and applications across major global markets.

Financial Context

  • Annual revenue reported at $67.22 million with quarterly revenue of $16.85 million
  • Current market cap stands at $240.96 million following a period of high volatility
  • Relative Strength Index of 37.0 suggests the stock is trading near technical support levels
  • Stock price recently closed at $8.36, significantly below the $20.27 Meiji entry price
Arcturus Therapeutics Holdings Inc. share price · last month
Line chart of Arcturus Therapeutics Holdings Inc.'s share price over the last month, from $10.42 on 19 Oct → $8.31 on 16 Nov; our story on 16 Nov at $8.36.

Down 0.6% since our story on 16 Nov: $8.36 when we broke it → $8.31 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$10.42
20 Oct$10.98
21 Oct$11.07
22 Oct$10.73
23 Oct$9.84
26 Oct$9.91
27 Oct$11.23
28 Oct$12.07
29 Oct$12.15
30 Oct$11.03
2 Nov$9.49
3 Nov$9.54
4 Nov$10.87
5 Nov$9.36
6 Nov$10.35
9 Nov$9.49
10 Nov$9.39
11 Nov$9.31
12 Nov$8.44
13 Nov$8.36
16 Nov$8.31

Management commentary

“The investment, together with the license agreement and the pandemic preparedness MOU, reflects Meiji’s confidence in our development capabilities and the potential of our technology platform.”

Joseph Payne, President and Chief Executive Officer of Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc. · financial snapshot
Share price$8.36
Market cap$241M
Revenue (annual)$67M
1-month price change-24.82%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Arcturus Therapeutics Holdings Inc. announcing a $50 million securities purchase agreement with Meiji Seika Pharma.

Read the filing ↗

Track Arcturus Therapeutics Holdings Inc. live

Get the next Arcturus Therapeutics Holdings Inc. SEC filing seconds after it lands.

More in Capital Raise

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.